How is von Willebrand factor (vWF) assessed in the evaluation of von Willebrand disease (vWD)?

Updated: Dec 30, 2019
  • Author: Eleanor S Pollak, MD; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
  • Print
Answer

vWF activity (the binding of VWF to platelet glycoprotein Ib [GPIb]) has traditionally been assessed by ristocetin cofactor (RCoF) activity. In this test, ristocetin is added to a suspension of washed formalin- or paraformaldehyde-fixed platelets in the presence of the patient's plasma (as a source of vWF). The rate of aggregation is then measured using an aggregometer, a device specifically designed to monitor this activity.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!